Dana-Farber Cancer Institute | Strategic Alliance Partners

March 23, 2022

Paul G. Richardson, MD, started his journey in medicine delivering tea and biscuits to patients and ended up making seminal advances in myeloma care.

March 22, 2022

The combination of abemaciclib and letrozole produced encouraging responses with an acceptable toxicity profile in patients with estrogen receptor–positive, recurrent or metastatic endometrial cancer with endometrioid histology, according to data from a phase 2 trial.

March 22, 2022

Toni K. Choueiri, MD, discusses follow-up data from the pivotal phase 3 KEYNOTE-564 examining adjuvant pembrolizumab in patients with clear cell RCC and additional areas that are ripe for further research.

March 21, 2022

Ursula A. Matulonis, MD, discusses the results of the phase 3 SORAYA trial in platinum-resistant ovarian cancer.

March 21, 2022

Harold J. Burstein, MD, PhD, discusses treatment updates across HER2-positive breast cancer, adjuvant advances in estrogen receptor–positive disease, and the domino effect of immunotherapy in triple-negative breast cancer.

March 18, 2022

Patients with recurrent ovarian cancer who received PARP inhibitor maintenance treatment in the second-line setting experienced a longer time to next treatment and overall survival compared with those who were just under active surveillance.

March 18, 2022

Pasi A. Jänne, MD, PhD, discovered a new way to treat lung cancer by following his intuition and staying flexible to pursue opportunities as they arise

March 11, 2022

Driven by his mother’s advice and his father’s memory, Richard M. Stone, MD, rose to become a global leader in leukemia care and research.

March 09, 2022

Sara M. Tolaney, MD, MPH, discusses pivotal trials in HER2-positive breast cancer.

March 04, 2022

Sara M. Tolaney, MD, MPH, discusses the efficacy of trastuzumab deruxtecan in the second-line setting and its potential to move into the first-line treatment of HER2-positive breast cancer.

March 02, 2022

Toni Choueiri, MD, discusses the design of the phase 3 KEYNOTE-564 trial in renal cell carcinoma.

February 28, 2022

A clinical algorithm-based approach that was developed to improve fractional polynomial model selection utilized additional criteria based on face validity, predictive accuracy, and expert opinion, which improved the plausibility of survival outcomes in patients with renal cell carcinoma.

February 23, 2022

Thomas A. Abrams, MD, discusses the next steps for exploration of cabozantinib plus atezolizumab in the treatment of microsatellite stable and mismatch repair proficient colorectal cancer.

February 22, 2022

Jacob Sands, MD, discusses biomarker testing in lung cancer, the utilization of neoadjuvant and frontline immunotherapy, and targeted therapy advances in non–small cell lung cancer.

February 21, 2022

OncLive® speaks with Drs. Toni Choueiri and Peter Van Veldhuizen on the latest studies in renal cell carcinoma that were presented during the 2022 Genitourinary Cancers Symposium.

February 20, 2022

Adjuvant pembrolizumab continued to demonstrate improved disease-free survival placebo in patients with renal cell carcinoma who are at high risk of recurrence.

February 19, 2022

OncLive® speaks with Drs. Jonathan Rosenberg and Guru Sonpavde on the groundbreaking research being presented in bladder cancer.

February 18, 2022

Thomas A. Abrams, MD, discusses the ongoing phase 1b COSMIC-021 trial examining cabozantinib/atezolizumab, the efficacy and safety demonstrated with the regimen in those with colorectal cancer, and the next steps for research

February 17, 2022

Androgen recepter positivity serves as an independent predictor of beneficial outcomes in breast cancer.

February 16, 2022

The administration of daily aspirin did not improve invasive disease-free survival in patients with high-risk, HER2-negative breast cancer.